On February 29, 2024 PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, reported the registration of Japan patent for its candidate drug, PMC-403, marking the third patent registration following Russia and Singapore (Press release, PharmAbcine, FEB 29, 2024, View Source;bmode=view&idx=18233718&t=board [SID1234649175]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PMC-403 is a novel first-in-class therapeutic antibody candidate with a unique mechanism of activating TIE2 receptors in endothelial cells. PMC-403 normalizes pathological leaky blood vessels by activating TIE2 receptors in endothelial cells. Through TIE2 activation, PMC-403 inhibits VEGFR-2 phosphorylation and maintains intercellular adhesion factors, thereby inhibiting vascular leakage caused by neovascularization.
The registered patent pertains to PMC-403’s TIE2-binding antibody compositions. Patent registrations are currently underway in countries including the United States, Europe, China, and Korea. The Company anticipates that the registrations in Japan, Russia and Singapore will positively impact registrations in other countries.
A representative from PharmAbcine stated, "Through the ongoing clinical trial, we expect to strengthen the exclusive rights of PMC-403 in major countries." They added, "Along with patent acquisition, we are eager to maximize the therapeutic potential of PMC-403 in various vessel-related diseases such as cancer, age-related macular degeneration, diabetic retinopathy, kidney disease, and many others."
With a mechanism distinct from currently available therapies, PMC-403 is undergoing Phase 1 clinical trial targeting patients with neovascular age-related macular degeneration in Korea. The evaluation of efficacy and safety in the third dosing group (3mg) is ongoing, following confirmation of safety in the second dosing group (2mg). After this is complete, both the last single-dose group (4mg) and the first multiple-dose group (MAD 3mg) will proceed simultaneously.